NCI-2021-03010

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors

This Phase 1 study is testing a new medicine called BGB-15025 to see if it's safe for people with advanced solid tumors. They're also looking to see if it works better when used with another medicine called Tislelizumab, which helps the immune system fight cancer.

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04649385

Clinical Trial Site: Sinai

To see all available clinical trials click here.